8-K: Cassava Sciences Licenses Simufilam Method of Treatment Patent from Yale University

Cassava Sciences secures an exclusive license from Yale University for intellectual property rights related to simufilam, a potential treatment for seizures associated with rare neurodevelopmental disorders like tuberous sclerosis complex (TSC).

Summary

• Cassava Sciences has entered into a license agreement with Yale University for exclusive worldwide rights to certain patent and intellectual property related to simufilam.
• The license covers the potential treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy and other potential indications.
• Yale's research, published in Science Translational Medicine, showed simufilam meaningfully reduced seizure frequency in an animal model of TSC.
• Cassava will pay Yale a nominal upfront license fee, up to $4.5 million in milestone payments, and tiered royalties on net sales, ranging from a lowto midsingle digit percentage.
• Minimum annual royalty payments range from the lowto midhundreds of thousands of dollars.
• The agreement continues until the last valid patent claim expires, the end of any government exclusivity period, or 10 years after the first sale of the licensed product.
• Cassava may terminate the agreement with advance notice or if Yale breaches the agreement.
• Yale may terminate the agreement if Cassava fails to make payments, breaches the agreement, defaults on obligations, fails to maintain insurance, or challenges Yale's patents.
• The agreement terminates automatically upon certain bankruptcy or insolvency events involving Cassava.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a new licensing agreement that expands Cassava Sciences' pipeline and potential therapeutic applications for simufilam. The agreement is based on promising research, and the company plans to collaborate with the TSC Alliance to further evaluate simufilam's potential. However, there are inherent risks in drug development, and the success of simufilam is not guaranteed.

Positives

• Cassava gains exclusive worldwide rights to develop and commercialize simufilam for TSC-related epilepsy and other potential indications.
• The license is based on promising research demonstrating simufilam's potential to reduce seizure frequency in an animal model.
• Collaboration with the TSC Alliance could accelerate the development and understanding of simufilam's efficacy.
• The agreement allows Cassava to sublicense the rights, potentially expanding its development and commercialization reach.
• The agreement includes customary confidentiality, reporting and inspection, and indemnification provisions.

Negatives

• Cassava is obligated to make milestone payments totaling up to $4.5 million and pay tiered royalties on net sales.
• The agreement includes termination clauses that could be triggered by Cassava's failure to meet certain obligations.
• The success of simufilam in treating TSC-related epilepsy is not guaranteed, and further research is needed.
• The agreement requires Cassava to use reasonable commercial efforts to implement a development and commercialization plan.

Risks

• Failure to successfully develop and commercialize simufilam could result in termination of the license agreement.
• Clinical trials may not replicate the positive results seen in the animal model.
• Regulatory approval for simufilam is not guaranteed.
• Competition from existing treatments for TSC-related epilepsy could limit simufilam's market potential.
• The agreement includes termination clauses that could be triggered by Cassava's failure to meet certain obligations, including financial and product development diligence.

Future Outlook

Cassava plans to conduct preclinical studies in collaboration with the TSC Alliance to further evaluate simufilam's potential as a treatment for TSC-related seizures and define next steps.

Management Comments

• Rick Barry, President and Chief Executive Officer of Cassava Sciences, stated that Dr. Bordeys research opens the door to a potential new therapeutic application for simufilam in the treatment of seizures related to rare neurodevelopmental disorders, including tuberous sclerosis complex.

Industry Context

This announcement positions Cassava Sciences to expand its focus beyond Alzheimer's disease into rare neurodevelopmental disorders, potentially diversifying its pipeline and addressing unmet medical needs in the treatment of TSC-related seizures. Other companies working in the epilepsy space include companies such as UCB, Takeda, and Eisai.

Comparison to Industry Standards

• Licensing agreements between universities and biotechnology companies are common in the pharmaceutical industry.
• The financial terms of this agreement, including upfront fees, milestone payments, and royalties, are within the typical range for similar licensing deals.
• For example, a similar deal might be the licensing of a novel drug target from a university to a biotech company, with upfront payments in the hundreds of thousands of dollars, milestone payments in the millions, and royalties in the single-digit percentages.
• The exclusive nature of the license provides Cassava with a competitive advantage in developing simufilam for TSC-related epilepsy.

Stakeholder Impact

• Shareholders may view the licensing agreement positively, as it expands Cassava Sciences' pipeline and potential market opportunities.
• Patients with TSC-related epilepsy may benefit from the development of a new treatment option.
• Yale University will receive financial compensation for its intellectual property and may benefit from the commercial success of simufilam.
• Employees of Cassava Sciences may be involved in the development and commercialization of simufilam for TSC-related epilepsy.

Next Steps

• Cassava plans to conduct preclinical studies in collaboration with the TSC Alliance.
• Cassava will further evaluate simufilam's potential as a treatment for TSC-related seizures.
• Cassava will define next steps for the development of simufilam for TSC-related seizures.

Key Dates